Do BPC-157 and TB-500 cause cancer?

The short answer

The worry is not made up, but the proof is thin on every side.

BPC-157 grows new blood vessels in rats. Thymosin beta-4, the full protein behind TB-500, raised blood vessel counts in mouse tumors. Tumors need new blood vessels to grow and spread, which is why a whole class of cancer drugs works by blocking that process. So the concern makes biological sense.

But "makes biological sense" is not the same as "shown in a study." For BPC-157, no study has reported it causing or speeding up a tumor. For thymosin beta-4, the parent protein of TB-500, one mouse experiment found it fed tumors that were already there. The study did not test whether it can start one.

Human evidence on either peptide and cancer? Close to zero.

Why people worry: new blood vessels

Angiogenesis is the process of forming new blood vessels from existing ones. Tumors hijack it. A growing tumor sends out signals, especially vascular endothelial growth factor (VEGF), that pull blood vessels toward it. Without that blood supply, a tumor stays tiny. With it, the tumor can grow and send cells into the bloodstream.

This is well understood enough that oncologists use drugs called angiogenesis inhibitors to block VEGF and starve tumors of blood.

BPC-157 does the opposite of those drugs. In rat muscle it raised blood vessel density, sped blood flow recovery in ischemic rat hind limbs, and switched on VEGFR2 signaling in human endothelial cells in a dish. In theory that could help healing. It is also why people ask about hidden tumors.

What the studies say about BPC-157

Our PubMed search on 3 November 2026 for BPC-157 together with cancer, tumor or carcinogen terms found 63 papers. None of them reports BPC-157 causing or promoting a tumor. The papers that touch cancer are reviews written by the Zagreb group that developed BPC-157, or with its lead researcher as co-author. One proposes using it for cancer cachexia. Another defends BPC-157 against theoretical concerns about angiogenesis. These are opinions, not independent experiments that tested whether BPC-157 feeds a tumor.

The FDA's 2026 briefing on BPC-157 states that no carcinogenicity studies exist, and the longest animal toxicity studies ran only 28 days.

So: nobody has shown BPC-157 causes cancer, and nobody has properly looked.

What the studies say about thymosin beta-4

Here the picture is different, and messier.

TB-500 is not the full thymosin beta-4 protein. It is a 7 amino acid fragment (residues 17 to 23) identified in a product labelled "TB-500" by a doping laboratory. The studies below tested the full protein, not this fragment. Nobody has tested whether the fragment affects tumors: FDA found no carcinogenicity studies of it.

The mouse melanoma study

This is the study behind the worry, and it deserves a close look.

Cha, Jeong and Kleinman (2003) took mouse melanoma cells and engineered them with a virus to produce extra thymosin beta-4. Then they put those cells into mice.

Injected under the skin: after 20 days, the tumors made with extra thymosin beta-4 were about 60 percent bigger (mean 21.7 mm vs 13.3 mm, P = .036). Injected into a vein: after 2 weeks the mice had about 4 times more tumor nodules in the lungs (46.7 vs 10.9, 20 mice). The tumors under the skin had 4.4 times more blood vessels, linked to more VEGF. In cells in a dish, migration was 2.3 times higher, with no change in proliferation or invasion.

The authors concluded that thymosin beta-4 "may stimulate tumor metastasis by activating cell migration and angiogenesis".

This matters, but the limits matter too. The cancer was put in first. The protein was produced inside the cancer cells, not injected. It was the full protein, not the TB-500 fragment. And it was mice.

Mixed findings in human tumor tissue

Researchers have measured thymosin beta-4 levels in tumors removed from cancer patients, and some have forced cancer cells to make more of it in the lab. The results go both ways.

In colon cancer cells in a dish, extra thymosin beta-4 increased invasion, and patients' liver metastases had higher levels than their original tumors. In colorectal cancer cells, it triggered epithelial-mesenchymal transition, a step toward spreading. A review noted higher levels across several metastatic tumor types and a link to VEGF.

Then there is the opposite. In multiple myeloma (298 patients), thymosin beta-4 was lower in cancer cells than in normal plasma cells. Myeloma cells made to produce more of it grew and moved less in lab tests, and mice injected with them lived longer (88.9 vs 65.9 days). In 209 patients treated with high-dose therapy and a stem cell transplant, below-median levels went with shorter event-free survival: 26.2 vs 37.6 months. In cervical cancer (42 tumor samples plus 15 with lymph node spread), levels rose at stage 1B but were lower in tumors that had spread to lymph nodes than in those that had not.

Some of these studies measured the body's own protein in tumor samples. Others forced cancer cells to make more of it. Nobody was given thymosin beta-4 as a drug.

What is known in humans

About 80 people have received BPC-157 in the five clinical studies FDA reviewed, for 2 weeks at most. The IV safety pilot gave 2 people 10 mg on day 1 and 20 mg on day 2, with no changes in heart, liver, kidney, thyroid, or glucose labs. No human study looked at cancer outcomes.

For the TB-500 fragment specifically, the FDA found zero articles in which it was administered to humans. About 2,190 people have been enrolled in 16 trials of the full thymosin beta-4 protein, placebo groups included. Most trials used eye drops, some skin gel, and about 280 people were enrolled in IV trials lasting 14 days or less. None of those trials was designed to look at cancer.

A clinician review in 2026 lists "pathological angiogenesis" and "carcinogenesis" among the potential risks of unregulated peptides including BPC-157 and TB-500, but as theoretical concerns, not observed cases.

One more thing worth knowing: products labelled TB-500 or TB-1000 did not consistently contain what the label said. So even the studies on the full protein may not apply to what is in the vial.

Both BPC-157 and thymosin beta-4 (plus its derivatives like TB-500) are on the WADA 2026 Prohibited List.

What this means for you

The proof that these peptides cause cancer is thin. But the proof that they are safe is just as thin.

BPC-157 has no cancer signal in any study, animal or human. That is reassuring, but it is also a small dataset with short follow-up and no carcinogenicity testing.

Thymosin beta-4, the full protein, has one mouse study that clearly showed it feeding implanted melanoma. It has mixed findings in human tumor tissue. And the TB-500 fragment has never been tested on its own in a human study.

If you have cancer or had cancer, I personally would not use TB-500.

We do not know enough. Not enough to say these peptides cause cancer. Not enough to say they do not.

I don't gatekeep.

Tell me what you're after and where you live. I'll email you my source.

Get George's source